## Analysis of Fragmentation of data

#1. Quantify fragmentation explicitly
Right now "22 repositories" is descriptive. Convert it to indices that other countries can be compared against:

Shannon entropy and Herfindahl–Hirschman Index (HHI) computed over the article-to-repository distribution. Higher entropy and lower HHI = more fragmentation. Compute these globally and within domain (e.g., only "general-purpose" repos: OSF, Zenodo, Figshare, Mendeley, Dryad, Dataverse — that's ~109 articles across 6 platforms, a textbook long tail).
Long-tail ratio: share of articles whose data sits in a repository used by fewer than, say, 10 Armenia papers. From your table, roughly half of repositories have <10 articles each — that's the discoverability problem in one number.
Deposition rate: 738 / 1,996 ≈ 37% of full-text-accessible articles have any link, and 738 / 2,712 ≈ 27% of all validated articles. This is arguably your headline finding — fragmentation is downstream of the bigger problem that most outputs deposit nothing.

#2. Separate the "domain-standard" repos from the "scattered" ones
A reviewer will push back: GenBank, PDB, GEO, SRA, ENA, PRIDE, dbSNP, ArrayExpress, BioProject are supposed to be where that data lives — they're international domain standards, and Leipzig Health Atlas doesn't replace them either. Your argument is stronger if you reframe it as a missing integration/discovery layer, not as "everything should be in one place." Split your table into:

Domain-standard archives (where deposition there is appropriate and good)
General-purpose repositories with no Armenia-specific findability (OSF, Zenodo, Figshare, Mendeley, Dryad, Dataverse — these are where the scattering really hurts)
Code/other (GitHub, GitLab, ClinicalTrials.gov)

Then the claim becomes: there is no national-level catalog that links across these, so a researcher cannot answer "what Armenian data exists on topic X?" in one query. That's exactly the gap Leipzig Health Atlas, FinnGen, Estonian Biobank, Health Data Hub (France), and BBMRI-ERIC fill at their respective levels.

#3. Measure findability and FAIRness directly
To prove that scattering causes friction rather than just asserting it:

Run F-UJI or FAIR-Checker on a stratified sample of the actual datasets (e.g., 30 per repository class). Report mean F/A/I/R subscores by repository type. The general-purpose long-tail repos almost always score worse on Interoperability and Reusability because metadata is freeform.
Time-to-locate experiment: define ~20 realistic research queries ("Armenian SARS-CoV-2 sequences 2021–2022", "Armenian cardiovascular cohort imaging", etc.). Have 2–3 researchers attempt to find relevant datasets and record (a) number of platforms queried, (b) total time, (c) success rate. Repeat the same protocol substituting Leipzig or Estonia as the target country. Even n=2 produces a publishable contrast.
Cross-linkage analysis: within your corpus, how often are two datasets from the same paper deposited in repositories that cross-link to each other? Build the article→dataset bipartite graph and report connected components and orphan rate.

#4. Reuse and citation analysis
This is the part that closes the loop from "harder to find" to "actually reused less":

Pull dataset-level citation counts from DataCite Event Data and Make Data Count for every accession you extracted that has a DOI. Compare reuse rates between (i) domain archives, (ii) general-purpose repos, (iii) datasets indexed by an integration platform like Leipzig Health Atlas for the comparator country.
For non-DOI accessions (GenBank, PDB, GEO, SRA), use EuropePMC's "cited by" / "linked entities" API — it surfaces papers that cite an accession in their text, which is the closest proxy for reuse in life sciences.
A clean dependent variable: median citations per dataset within 24 months of deposition, stratified by repository class and country.

#5. Comparative framework
Pick 2–4 comparators rather than one. Leipzig Health Atlas is good but it's regional; for a fair comparison, you want a range:

Country-scale with a centralized integration layer: Estonia (Estonian Biobank + e-Health), Finland (FinnGen + Findata), Denmark (national registers).
Regional/thematic hub: Leipzig Health Atlas, Catalonia (IMPaCT-Data).
Comparable-size country without a national hub: Georgia, Moldova, North Macedonia, or another small post-Soviet country. This is critical — comparing Armenia only to Finland invites the "of course, they have more money" objection. Showing that Armenia also lags peers of similar size and budget makes the case structural rather than just resource-based.

For each, replicate your pipeline: same PubMed affiliation query, same year range, same repository extraction, same fragmentation indices, same FAIR sample, same reuse counts. Then your contribution isn't an opinion piece — it's a comparative bibliometric study with a defensible method.

#6. One reframing worth considering
The strongest version of your argument is probably two findings in tension:

Armenia's deposition rate is low (~27%) — a sharing problem.
Of what is deposited, no country-level discovery layer exists — a reuse/findability problem.

## Final thoughts
A centralized national platform addresses the second directly, and (as the Finnish and Estonian experiences suggest) tends to pull up the first by giving researchers a default, easy place to deposit. That's the policy implication your data actually supports, and it's cleaner than arguing centralization is intrinsically better.
